Excelsior Biopharma Valuation
| 6496 Stock | TWD 29.10 0.40 1.36% |
At this time, the firm appears to be overvalued. Excelsior Biopharma shows a prevailing Real Value of NT$25.15 per share. The current price of the firm is NT$29.1. Our model computes the value of Excelsior Biopharma from reviewing the firm fundamentals such as Profit Margin of (0.04) %, current valuation of 577.51 M, and Operating Margin of (0.04) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Excelsior Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Excelsior Biopharma is based on 3 months time horizon. Increasing Excelsior Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Excelsior stock is determined by what a typical buyer is willing to pay for full or partial control of Excelsior Biopharma. Since Excelsior Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Excelsior Stock. However, Excelsior Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 29.1 | Real 25.15 | Hype 29.1 |
The intrinsic value of Excelsior Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Excelsior Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Excelsior Biopharma helps investors to forecast how Excelsior stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Excelsior Biopharma more accurately as focusing exclusively on Excelsior Biopharma's fundamentals will not take into account other important factors: Excelsior Biopharma Total Value Analysis
Excelsior Biopharma is presently anticipated to have takeover price of 577.51 M with market capitalization of 1.32 B, debt of 293.99 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Excelsior Biopharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
577.51 M | 1.32 B | 293.99 M |
Excelsior Biopharma Investor Information
About 61.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.09. In the past many companies with similar price-to-book ratios have beat the market. Excelsior Biopharma recorded a loss per share of 0.63. The entity last dividend was issued on the 13th of July 2021. Based on the key measurements obtained from Excelsior Biopharma's financial statements, Excelsior Biopharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Excelsior Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Excelsior Biopharma has an asset utilization ratio of 72.78 percent. This indicates that the Company is making NT$0.73 for each dollar of assets. An increasing asset utilization means that Excelsior Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Excelsior Biopharma Ownership Allocation
Excelsior Biopharma holds a total of 46.69 Million outstanding shares. Excelsior Biopharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.0 percent of Excelsior Biopharma outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Excelsior Biopharma Profitability Analysis
The company reported the revenue of 1.34 B. Net Loss for the year was (15.65 M) with profit before overhead, payroll, taxes, and interest of 293.35 M.About Excelsior Biopharma Valuation
Our relative valuation model uses a comparative analysis of Excelsior Biopharma. We calculate exposure to Excelsior Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Excelsior Biopharma's related companies.8 Steps to conduct Excelsior Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Excelsior Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Excelsior Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Excelsior Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Excelsior Biopharma's revenue streams: Identify Excelsior Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Excelsior Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Excelsior Biopharma's growth potential: Evaluate Excelsior Biopharma's management, business model, and growth potential.
- Determine Excelsior Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Excelsior Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Excelsior Stock Analysis
When running Excelsior Biopharma's price analysis, check to measure Excelsior Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Excelsior Biopharma is operating at the current time. Most of Excelsior Biopharma's value examination focuses on studying past and present price action to predict the probability of Excelsior Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Excelsior Biopharma's price. Additionally, you may evaluate how the addition of Excelsior Biopharma to your portfolios can decrease your overall portfolio volatility.